Industry: Healthcare
Published Date: August-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 190
Report ID: PMRREP34626
1. Executive Summary
1.1. Global Allogeneic Cell Therapy Market Snapshot, 2024 and 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Epidemiology - Disease Prevalence and Incidence
3.2. Technology Assessment
3.3. Regulatory Landscape
3.4. Value Chain Analysis
3.5. Key Deals and Mergers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis
4. Global Allogeneic Cell Therapy Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2018-2022
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
4.3. Global Allogeneic Cell Therapy Market Outlook: Therapy Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Therapy Type, 2018 - 2022
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2023 - 2031
4.3.3.1. Stem Cell Therapies
4.3.3.2. Non-stem Cell Therapies
4.4. Market Attractiveness Analysis: Therapy Type
4.5. Global Allogeneic Cell Therapy Market Outlook: Therapeutic Area
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Therapeutic Area, 2018 - 2022
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
4.5.3.1. Hematological Disorders
4.5.3.2. Dermatological Disorders
4.5.3.3. Oncological Disorders
4.5.3.4. Neurological Disorders
4.5.3.5. Others
4.6. Market Attractiveness Analysis: Therapeutic Area
5. Global Allogeneic Cell Therapy Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2018 - 2022
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2023 - 2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Allogeneic Cell Therapy Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Therapy Type
6.3.3. By Therapeutic Area
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
6.4.1. U.S.
6.4.2. Canada
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2023 - 2031
6.5.1. Stem Cell Therapies
6.5.2. Non-stem Cell Therapies
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
6.6.1. Hematological Disorders
6.6.2. Dermatological Disorders
6.6.3. Oncological Disorders
6.6.4. Neurological Disorders
6.6.5. Others
6.7. Market Attractiveness Analysis
7. Europe Allogeneic Cell Therapy Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Therapy Type
7.3.3. By Therapeutic Area
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
7.4.1. Germany
7.4.2. France
7.4.3. U.K.
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Türkiye
7.4.8. Rest of Europe
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2023 - 2031
7.5.1. Stem Cell Therapies
7.5.2. Non-stem Cell Therapies
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
7.6.1. Hematological Disorders
7.6.2. Dermatological Disorders
7.6.3. Oncological Disorders
7.6.4. Neurological Disorders
7.6.5. Others
7.7. Market Attractiveness Analysis
8. East Asia Allogeneic Cell Therapy Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Therapy Type
8.3.3. By Therapeutic Area
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
8.4.1. China
8.4.2. Japan
8.4.3. South Korea
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2023 - 2031
8.5.1. Stem Cell Therapies
8.5.2. Non-stem Cell Therapies
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
8.6.1. Hematological Disorders
8.6.2. Dermatological Disorders
8.6.3. Oncological Disorders
8.6.4. Neurological Disorders
8.6.5. Others
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Allogeneic Cell Therapy Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Therapy Type
9.3.3. By Therapeutic Area
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
9.4.1. India
9.4.2. Southeast Asia
9.4.3. ANZ
9.4.4. Rest of South Asia & Oceania
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2023 - 2031
9.5.1. Stem Cell Therapies
9.5.2. Non-stem Cell Therapies
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
9.6.1. Hematological Disorders
9.6.2. Dermatological Disorders
9.6.3. Oncological Disorders
9.6.4. Neurological Disorders
9.6.5. Others
9.7. Market Attractiveness Analysis
10. Latin America Allogeneic Cell Therapy Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Therapy Type
10.3.3. By Therapeutic Area
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2023 - 2031
10.5.1. Stem Cell Therapies
10.5.2. Non-stem Cell Therapies
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
10.6.1. Hematological Disorders
10.6.2. Dermatological Disorders
10.6.3. Oncological Disorders
10.6.4. Neurological Disorders
10.6.5. Others
10.7. Market Attractiveness Analysis
11. Middle East & Africa Allogeneic Cell Therapy Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
11.1. Key Highlights
11.2. Pricing Analysis
11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2018 - 2022
11.3.1. By Country
11.3.2. By Therapy Type
11.3.3. By Therapeutic Area
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
11.4.1. GCC Countries
11.4.2. Egypt
11.4.3. South Africa
11.4.4. Northern Africa
11.4.5. Rest of Middle East & Africa
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapy Type, 2023 - 2031
11.5.1. Stem Cell Therapies
11.5.2. Non-stem Cell Therapies
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
11.6.1. Hematological Disorders
11.6.2. Dermatological Disorders
11.6.3. Oncological Disorders
11.6.4. Neurological Disorders
11.6.5. Others
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. SSM Cardinal Glennon Children's Medical Center
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Cleveland Cord Blood Center
12.3.2.1. Overview
12.3.2.2. Segments and Products
12.3.2.3. Key Financials
12.3.2.4. Market Developments
12.3.2.5. Market Strategy
12.3.3. Duke University School of Medicine
12.3.3.1. Overview
12.3.3.2. Segments and Products
12.3.3.3. Key Financials
12.3.3.4. Market Developments
12.3.3.5. Market Strategy
12.3.4. New York Blood Center
12.3.4.1. Overview
12.3.4.2. Segments and Products
12.3.4.3. Key Financials
12.3.4.4. Market Developments
12.3.4.5. Market Strategy
12.3.5. Clinimmune Labs, University of Colorado Cord Blood Bank
12.3.5.1. Overview
12.3.5.2. Segments and Products
12.3.5.3. Key Financials
12.3.5.4. Market Developments
12.3.5.5. Market Strategy
12.3.6. MD Anderson Cord Blood Bank
12.3.6.1. Overview
12.3.6.2. Segments and Products
12.3.6.3. Key Financials
12.3.6.4. Market Developments
12.3.6.5. Market Strategy
12.3.7. LifeSouth Community Blood Centers, Inc.
12.3.7.1. Overview
12.3.7.2. Segments and Products
12.3.7.3. Key Financials
12.3.7.4. Market Developments
12.3.7.5. Market Strategy
12.3.8. Bloodworks Northwest
12.3.8.1. Overview
12.3.8.2. Segments and Products
12.3.8.3. Key Financials
12.3.8.4. Market Developments
12.3.8.5. Market Strategy
12.3.9. JCR Pharmaceuticals Co., Ltd.
12.3.9.1. Overview
12.3.9.2. Segments and Products
12.3.9.3. Key Financials
12.3.9.4. Market Developments
12.3.9.5. Market Strategy
12.3.10. Sumitomo Pharma Co., Ltd.
12.3.10.1. Overview
12.3.10.2. Segments and Products
12.3.10.3. Key Financials
12.3.10.4. Market Developments
12.3.10.5. Market Strategy
12.3.11. Atara Biotherapeutics
12.3.11.1. Overview
12.3.11.2. Segments and Products
12.3.11.3. Key Financials
12.3.11.4. Market Developments
12.3.11.5. Market Strategy
12.3.12. Mallinckrodt Pharmaceuticals
12.3.12.1. Overview
12.3.12.2. Segments and Products
12.3.12.3. Key Financials
12.3.12.4. Market Developments
12.3.12.5. Market Strategy
12.3.13. Tego Science Inc
12.3.13.1. Overview
12.3.13.2. Segments and Products
12.3.13.3. Key Financials
12.3.13.4. Market Developments
12.3.13.5. Market Strategy
12.3.14. Takeda Pharmaceutical Company Limited
12.3.14.1. Overview
12.3.14.2. Segments and Products
12.3.14.3. Key Financials
12.3.14.4. Market Developments
12.3.14.5. Market Strategy
12.3.15. STEMPEUTICS RESEARCH PVT LTD
12.3.15.1. Overview
12.3.15.2. Segments and Products
12.3.15.3. Key Financials
12.3.15.4. Market Developments
12.3.15.5. Market Strategy
12.3.16. Biosolution Co., Ltd.
12.3.16.1. Overview
12.3.16.2. Segments and Products
12.3.16.3. Key Financials
12.3.16.4. Market Developments
12.3.16.5. Market Strategy
12.3.17. MEDIPOST Co., Ltd.
12.3.17.1. Overview
12.3.17.2. Segments and Products
12.3.17.3. Key Financials
12.3.17.4. Market Developments
12.3.17.5. Market Strategy
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
